Sign in
Active, not recruitingNo phase

ALTERRA Post-Approval Study

Key facts

Who runs it
Edwards Lifesciences
Where
Aurora, Birmingham, Boston, Cincinnati, Columbus, Dallas, Durham, Gainesville, Houston, Little Rock, Los Angeles, Memphis, New York, Oak Lawn, Pittsburgh, Salt Lake City, San Diego, Seattle, St Louis, Stanford, and Tampa, United StatesSee the 23 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
People taking part
150 people enrolled
Started
12 May 2022
Expected to end
Jul 2035
Type of study
Observational
Treatments tested
  • Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
Record updated
5 October 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Native or surgically-repaired RVOT with severe PR
  • Clinically indicated for pulmonary valve replacement
  • Planned for treatment with the Alterra prestent and SAPIEN 3 THV

Who cannot take part

  • Active bacterial endocarditis or other active infections
  • Inability to tolerate an anticoagulation/antiplatelet regimen

Where in United States

Also in 1 other country, 1 site

  • Colorado Children's HospitalAurora, United States
  • Children's of AlabamaBirmingham, United States
  • Boston Children's HospitalBoston, United States
  • Cincinnati Children's HospitalCincinnati, United States
  • Nationwide Children's HospitalColumbus, United States
  • Medical City DallasDallas, United States
  • Duke UniversityDurham, United States
  • UF Health Shands HospitalGainesville, United States
  • Children's Memorial Hermann HospitalHouston, United States
  • Texas Children's HospitalHouston, United States
  • Arkansas Children's HospitalLittle Rock, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Le Bonheur Children's HospitalMemphis, United States
  • Columbia UniversityNew York, United States
  • Icahn School of Medicine at Mount SinaiNew York, United States
  • Advocate Children's HospitalOak Lawn, United States
  • UPMC Children's Hospital of PittsburghPittsburgh, United States
  • Primary Children's HospitalSalt Lake City, United States
  • Rady Children's HospitalSan Diego, United States
  • Seattle Children's HospitalSeattle, United States
  • Washington University in St. LouisSt Louis, United States
  • Stanford UniversityStanford, United States
  • St. Joseph's Children's HospitalTampa, United States

About the trial

What the trial wants to find out

This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting

The group in the trial

  • TPVR

    Transcatheter Pulmonary Valve Replacement

    Treatment: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter Post-Approval Study of Congenital Pulmonic Valve Dysfunction Studying the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System With Alterra Adaptive Prestent
Record updated
5 October 2026